Close Menu
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
What's Hot

Acquisition of Tribe Capital begins a new chapter in the evolution of crypto exchanges

November 19, 2026

U.S. Court of Appeals Allows President Trump to End TPS Deportation Protections for Venezuelans | Court News

November 19, 2026

Novartis raises forecasts for blockbuster drug as it seeks to prove growth can be sustained

November 19, 2026
Facebook X (Twitter) Instagram
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Facebook X (Twitter) Instagram
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Home » Novartis raises forecasts for blockbuster drug as it seeks to prove growth can be sustained
World

Novartis raises forecasts for blockbuster drug as it seeks to prove growth can be sustained

Editor-In-ChiefBy Editor-In-ChiefNovember 19, 2026No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email


Pharmaceutical major Novartis Investors are increasingly optimistic about some of the company’s biggest growth drugs, even as they question whether the company can maintain growth beyond 2031 and offset the financial impact of patent expirations on older drugs.

The Swiss drugmaker now expects peak sales of $18 billion for its multiple sclerosis drug Kesimpta, leukemia drug Cemblix and cholesterol drug Lekvio, exceeding previous estimates of $14 billion.

CEO Vasu Narasimhan said the upgrade was driven primarily by strong commercial performance, pointing to the growing market share of Kesimpta and Cembrix in the US and Asia, as well as strong demand for Lekvio.

Vasu Narasimhan, CEO of Novartis AG, makes a presentation in the Roosevelt Room of the White House on Friday, December 19, 2025 in Washington, DC, USA.

Will Oliver | Bloomberg | Getty Images

“What’s driving these upgrades is really the commercial performance in the market,” Narasimhan told reporters Thursday.

Shares fell 2.4% in mid-morning trading in Switzerland. The question for investors will be whether these drugs can grow fast enough to offset the loss in sales as other drugs face competition from cheaper rivals entering the market.

Stock chart iconStock chart icon

Novartis stock price since the beginning of the year.

Still, despite stronger expectations for some key growth drugs, the overall growth outlook looked slightly cautious.

Novartis forecasts annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of 5% to 6% through 2030, but over a five-year period.

Chief Executive Basu Narasimhan said the revised outlook reflects the company’s expected entry into generic competition for its breast cancer drug Kisqari in the United States in the second half of 2031.

Citi analysts noted that the 2031 revenue outlook is about 3% above consensus, adding that they expect the market to remain skeptical about growth beyond 2031 until more pipeline data is available.

Cholesterol drug setback casts doubt on multibillion-dollar competition

Novartis has faced several clinical setbacks recently. The high-profile cardiovascular peracalcen trial in September showed no improvement in cardiovascular outcomes. The next day, the company’s drug deldesiran, which treats muscle-wasting disorders, failed in a late-stage trial, sending the stock down nearly 11%, its worst single-day decline since 1987.

Narasimhan defended the drug company’s capital allocation strategy after the failure of its investigational drug derdesirane, which it acquired in a $12 billion deal with Avidity Biosciences earlier this year.

Narasimhan said shareholders have differing views on the deal, with some favoring a more aggressive deal and others favoring a different approach. But he said Novartis remains confident in its strategy, noting that the company is a top performer in its sector with total shareholder returns of 275% over the past 10 years.

Tune in to Novartis CEO Vasu Narasimhan’s appearance on CNBC TV at 11 a.m. ET. Watch in real time on CNBC+ or CNBC Pro streams.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor-In-Chief
  • Website

Related Posts

U.S. Treasury yields: investors assess the current state of the U.S. economy

November 19, 2026

Today’s Most Moving Stocks: Live Updates

November 19, 2026

Anthropic IPO creates thousands of millionaire employees

November 19, 2026
Add A Comment

Comments are closed.

News

U.S. Court of Appeals Allows President Trump to End TPS Deportation Protections for Venezuelans | Court News

By Editor-In-ChiefNovember 19, 2026

The appeals court’s ruling prevents a lower court ruling blocking President Trump from ending the…

‘On the same page’: Hegseth praises relations between US and Colombia’s de la Espriela Politics News

November 19, 2026

‘Not an acquittal’: Hegseth remains under microscope after impeachment vote | Political News

November 19, 2026
Top Trending

Anthropic CEO recommits to adjusting pace of AI development at Nasdaq opening bell

By Editor-In-ChiefNovember 19, 2026

As Anthropic debuted on Wall Street Thursday in its largest IPO in…

Anthropic trades at $111 on Nasdaq, 33% above IPO price

By Editor-In-ChiefNovember 19, 2026

Anthropic’s stock currently trades on the Nasdaq exchange, and the company has…

Former Alibaba executive’s Everfull raises $48.5 million to connect retailers with factories in China

By Editor-In-ChiefNovember 19, 2026

Everful, a San Francisco and Singapore-based startup that connects small retailers and…

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Welcome to WhistleBuzz.com (“we,” “our,” or “us”). Your privacy is important to us. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our website https://whistlebuzz.com/ (the “Site”). Please read this policy carefully to understand our views and practices regarding your personal data and how we will treat it.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Facebook X (Twitter) Instagram Pinterest
  • Home
  • Advertise With Us
  • Contact US
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • About US
© 2026 whistlebuzz. Designed by whistlebuzz.

Type above and press Enter to search. Press Esc to cancel.